Omvoh
(Mirikizumab)ApprovedMonoclonal antibody
Eli LillyOmvoh is a monoclonal antibody that works as a Il-23p19 Inhibitor.[2] It is being used across 9 indications, with its most advanced program in Approved.[1]
Omvoh is one of 196 monoclonal antibody programs targeting Psoriasis Vulgaris. It is currently in Approved.
9
Indications
43
Total Trials
21
Active Trials
195
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Omvoh
Eli LillyApproved
Cosentyx
NovartisPreclinical
Stelara
Johnson & JohnsonPreclinical
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ulcerative Colitis14 trials
Show 11 more trials
ART9 trials
Show 6 more trials
Crohn's Disease6 trials
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Not yet recruiting·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Phase 4·NCT07292012·110 enrolled
Psoriasis5 trials
8 more indications
Inflammatory Conditions1 trial
Effectiveness1 trial
Stricture1 trial
Ulcerative Colitis (UC)1 trial
Colitis, Ulcerative1 trial
Crohn Disease1 trial
Chrohn's Disease1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Oct 26, 2023
OMVOH
BLA BLA761279
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mirikizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]